AFG
OBIO icon

ABLE Financial Group’s Orchestra BioMed OBIO Stock Holding History

ABLE Financial Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57K Hold
13,402
– – 0.01% 206
2025
Q4 		$55.6K Hold
13,402
– – 0.01% 210
2025
Q3 		$33.2K Hold
13,402
– – 0.01% 205
2025
Q2 		$35.9K Hold
13,402
– – 0.01% 204
2025
Q1 		$57.4K Hold
13,402
– – 0.02% 196
2024
Q4 		$53.6K Hold
13,402
– – 0.02% 192
2024
Q3 		$68.9K Buy
+13,402
New +$87.5K 0.02% 187

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ABLE Financial Group's OBIO Position: Q1 2026 in Review

ABLE Financial Group held its Orchestra BioMed (OBIO) position steady in Q1 2026 at 13,402 shares worth $57K. The position accounts for 0.01% of the portfolio, ranked #206.

ABLE Financial Group first reported a position in OBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $68.9K in Q3 2024. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • ABLE Financial Group held 13,402 shares of Orchestra BioMed worth $57K as of Q1 2026.
  • ABLE Financial Group left its Orchestra BioMed share count unchanged in Q1 2026.
  • Orchestra BioMed made up 0.01% of ABLE Financial Group's portfolio in Q1 2026, its #206 holding.
  • ABLE Financial Group first reported a position in Orchestra BioMed in Q3 2024 and has held it in 7 quarters since.
  • ABLE Financial Group's Orchestra BioMed position peaked at $68.9K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on ABLE Financial Group's 13F filing for Q1 2026, filed 21 Apr 2026.